Your browser doesn't support javascript.
loading
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.
Mørk, Sofie Kirial; Kongsted, Per; Westergaard, Marie Christine Wulff; Albieri, Benedetta; Granhøj, Joachim Stoltenborg; Donia, Marco; Martinenaite, Evelina; Holmström, Morten Orebo; Madsen, Kasper; Kverneland, Anders H; Kjeldsen, Julie Westerlin; Holmstroem, Rikke Boedker; Lorentzen, Cathrine Lund; Nørgaard, Nis; Andreasen, Lars Vibe; Wood, Grith Krøyer; Christensen, Dennis; Klausen, Michael Schantz; Hadrup, Sine Reker; Thor Straten, Per; Andersen, Mads Hald; Svane, Inge Marie.
Afiliação
  • Mørk SK; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Kongsted P; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Westergaard MCW; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Albieri B; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Granhøj JS; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Donia M; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Martinenaite E; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Holmström MO; IO Biotech Aps, Copenhagen, Denmark.
  • Madsen K; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Kverneland AH; Department of Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
  • Kjeldsen JW; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Holmstroem RB; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Lorentzen CL; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Nørgaard N; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Andreasen LV; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
  • Wood GK; Department of Urology, Copenhagen University Hospital, Herlev, Denmark.
  • Christensen D; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark.
  • Klausen MS; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark.
  • Hadrup SR; Statens Serum Institut, Center for Vaccine Research, Copenhagen, Denmark.
  • Thor Straten P; EVAXION BIOTECH A/S, Hørsholm, Denmark.
  • Andersen MH; Department of Health Technology, Technical University of Denmark (DTU), HEALTH TECH, Kongens Lyngby, Denmark.
  • Svane IM; Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, Denmark.
Front Immunol ; 14: 1122977, 2023.
Article em En | MEDLINE | ID: mdl-36999039
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Vacinas Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Vacinas Tipo de estudo: Prognostic_studies Limite: Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article